Where isatuximab may fit in the treatment paradigm for relapsed/refractory multiple myeloma

FAQ Library published on February 23, 2018
Download Transcript Download Audio
Paul G. Richardson, MD
R.J. Corman Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Welcome to Managing Myeloma. My name is Dr. Paul Richardson. It is my pleasure to tell you a little bit about the novel agent isatuximab, and how, if it is approved as a next-generation or subsequent CD38 targeted monoclonal antibody after daratumumab, how we might think about where this drug might belong in terms of positioning for the treatment paradigm in relapsed/refractory myeloma. It is important to note that isatuximab has a strong potent component to its activity based upon the apoptotic pathway. The other thing that is important about it is it has a shorter infusion time and a friendlier schedule, in that after the initial cycle of weekly isatuximab we can move to two weekly infusions and hold steady at that rate. In the context of its use in terms of relapsed/refractory patients, it may be more convenient and somewhat better tolerated than other antibodies in this class. Having said that, direct comparisons are not yet available. Suffice to say, this may constitute an important backbone agent to which other drugs can be easily combined, and can confer clinical benefit to our patients. Thank you for viewing this activity.

Last modified: February 19, 2018
Related Items by Author
The what, how, and when of CAR-T therapy in multiple myeloma
Paul G. Richardson, MD
FAQ Library published on October 24, 2018
What are the available options for patients relapsing beyond the third line of therapy?
Paul G. Richardson, MD
FAQ Library published on October 10, 2018
What are truly myeloma defining events, and how will their assessment impact on clinical practice?
Paul G. Richardson, MD
FAQ Library published on May 5, 2016
How can we effectively address medication compliance and adherence in the outpatient setting to oral medicines that we use in myeloma?
Paul G. Richardson, MD
FAQ Library published on April 18, 2016
The Revised International Staging System (R-ISS)
Paul G. Richardson, MD
FAQ Library published on April 7, 2016
What is the role of consolidation therapy in multiple myeloma and is there a best approach?
Paul G. Richardson, MD
FAQ Library published on September 4, 2013
What are some interventions for asthenia?
Paul G. Richardson, MD
FAQ Library published on May 13, 2011 in Comorbidities/SEs, Patient Communication
How do we manage pain in myeloma patients?
Paul G. Richardson, MD
FAQ Library published on October 12, 2009 in Comorbidities/SEs
How do I manage bone disease in my myeloma patients?
Paul G. Richardson, MD
FAQ Library published on October 12, 2009 in Comorbidities/SEs, Bone Disease